Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

U.S. stocks roared back on Friday to nearly halve their losses from what was tracking to be one of the market’s worst weeks ...

Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

Employees of the coffee chain launched a five-day action in Chicago, Los Angeles and Seattle after the union called for a strike. Eli Lilly is now comfortably ahead of Novo Nordisk in the race to ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed that ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...